PharmaLive: FDA Approves Intuniv (guanfacine) Extended-Release Tablets for Use as Adjunctive Therapy to Stimulants for the Treatment of ADHD in Children and Adolescents
Links shared publicly online about this topic.
- 473total visits
PharmaLive: FDA Approves Intuniv (guanfacine) Extended-Release Tablets for Use as Adjunctive Therapy to Stimulants for the Treatment of ADHD in Children and Adolescents
View full resource at pharmalive.com
Tags: ADHD, ADHD Medication, Children's Health, FDA, Intuniv, Pediatric ADHD
Most Recently Shared on February 28, 2011 at 7:27 pm By:
Daily Advantage - FDA OKs Wider Intuniv Use - http://tinyurl.com/4on7zsc
FDA approves guanfacine ER tablets to treat ADHD in children, teens - - Drug Topics
drugtopics.modernmedicine.com — “FDA approved the use of once-daily guanfacine (Intuniv, Shire) extended-release tablets as adjunctive therapy to stimulants for the treatment of attention deficit hyperactivity disorder in children and adolescents aged 6 to 17 years as part of a total treatment program.” View full resource at drugtopics.modernmedicine.com
Most Recently Shared on March 2, 2011 at 7:52 pm By:
FDA approves guanfacine ER tablets to treat ADHD in children, teens: FDA approved the use of once-daily gu... http://bit.ly/hRwbtM #adhd
Intuniv gains indication as adjunctive therapy in ADHD - MPR
empr.com — “Shire announced that the FDA has approved Intuniv (guanfacine extended-release tablets) for use as adjunctive therapy to stimulants for the treatment of attention deficit hyperactivity disorder (ADHD) in children and adolescents 6--17 years as part of a total treatment program.” View full resource at empr.com
Most Recently Shared on February 28, 2011 at 3:44 pm By:
MPR News: Intuniv gains indication as adjunctive therapy in ADHD: Shire announced that the FDA has approved Intu... http://bit.ly/eyR7Gr
Intuniv gains indication as adjunctive therapy in ADHD - ONA
oncologynurseadvisor.com — “Shire announced that the FDA has approved Intuniv (guanfacine extended-release tablets) for use as adjunctive therapy to stimulants for the treatment of attention deficit hyperactivity disorder (ADHD) in children and adolescents 6--17 years as part of a total treatment program.” View full resource at oncologynurseadvisor.com
Most Recently Shared on February 28, 2011 at 3:40 pm By:
OncologyNurseAdvisor Oncology, Nursing, Medical Education, and Medical Publisher
Intuniv gains indication as adjunctive therapy in ADHD http://goo.gl/fb/srbUs
Advertisement
